<?xml version='1.0' encoding='utf-8'?>
<document id="22114934"><sentence text="AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus." /><sentence text="Co-administration of anti-tuberculosis and antiretroviral therapy is often inevitable in high-burden countries where tuberculosis is the most common opportunistic infection associated with HIV/AIDS" /><sentence text=" Concurrent use of rifampicin and several antiretroviral drugs is complicated by pharmacokinetic drug-drug interaction"><entity charOffset="19-29" id="DDI-PubMed.22114934.s3.e0" text="rifampicin" /></sentence><sentence text="" /><sentence text="Pubmed and Google search following the key words tuberculosis, HIV, emtricitabine, tenofovir efavirenz, interaction were used to find relevant information on each drug of the fixed dose combination AtriplaR RESULTS: Information on generic name, trade name, pharmacokinetic parameter, metabolism and the pharmacokinetic interaction with Anti-TB drugs of emtricitabine, tenofovir, and efavirenz was obtained"><entity charOffset="68-81" id="DDI-PubMed.22114934.s5.e0" text="emtricitabine" /><entity charOffset="83-102" id="DDI-PubMed.22114934.s5.e1" text="tenofovir efavirenz" /><entity charOffset="353-366" id="DDI-PubMed.22114934.s5.e2" text="emtricitabine" /><entity charOffset="368-377" id="DDI-PubMed.22114934.s5.e3" text="tenofovir" /><entity charOffset="383-392" id="DDI-PubMed.22114934.s5.e4" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.22114934.s5.e0" e2="DDI-PubMed.22114934.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22114934.s5.e0" e2="DDI-PubMed.22114934.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22114934.s5.e0" e2="DDI-PubMed.22114934.s5.e2" /><pair ddi="false" e1="DDI-PubMed.22114934.s5.e0" e2="DDI-PubMed.22114934.s5.e3" /><pair ddi="false" e1="DDI-PubMed.22114934.s5.e0" e2="DDI-PubMed.22114934.s5.e4" /><pair ddi="false" e1="DDI-PubMed.22114934.s5.e1" e2="DDI-PubMed.22114934.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22114934.s5.e1" e2="DDI-PubMed.22114934.s5.e2" /><pair ddi="false" e1="DDI-PubMed.22114934.s5.e1" e2="DDI-PubMed.22114934.s5.e3" /><pair ddi="false" e1="DDI-PubMed.22114934.s5.e1" e2="DDI-PubMed.22114934.s5.e4" /><pair ddi="false" e1="DDI-PubMed.22114934.s5.e2" e2="DDI-PubMed.22114934.s5.e2" /><pair ddi="false" e1="DDI-PubMed.22114934.s5.e2" e2="DDI-PubMed.22114934.s5.e3" /><pair ddi="false" e1="DDI-PubMed.22114934.s5.e2" e2="DDI-PubMed.22114934.s5.e4" /><pair ddi="false" e1="DDI-PubMed.22114934.s5.e3" e2="DDI-PubMed.22114934.s5.e3" /><pair ddi="false" e1="DDI-PubMed.22114934.s5.e3" e2="DDI-PubMed.22114934.s5.e4" /></sentence><sentence text="" /><sentence text="Fixed dose combination of emtricitabine/tenofovir/efavirenz (ATRIPLAR) which has been approved by Food and Drug Administration shows promising results as far as safety and efficacy is concerned in TB/HIV co-infection patients, hence can be considered effective and safe antiretroviral drug in TB/HIV management for adult and children above 3 years of age"><entity charOffset="26-39" id="DDI-PubMed.22114934.s7.e0" text="emtricitabine" /><entity charOffset="40-49" id="DDI-PubMed.22114934.s7.e1" text="tenofovir" /><entity charOffset="50-59" id="DDI-PubMed.22114934.s7.e2" text="efavirenz" /><entity charOffset="61-69" id="DDI-PubMed.22114934.s7.e3" text="ATRIPLAR" /><pair ddi="false" e1="DDI-PubMed.22114934.s7.e0" e2="DDI-PubMed.22114934.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22114934.s7.e0" e2="DDI-PubMed.22114934.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22114934.s7.e0" e2="DDI-PubMed.22114934.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22114934.s7.e0" e2="DDI-PubMed.22114934.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22114934.s7.e1" e2="DDI-PubMed.22114934.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22114934.s7.e1" e2="DDI-PubMed.22114934.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22114934.s7.e1" e2="DDI-PubMed.22114934.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22114934.s7.e2" e2="DDI-PubMed.22114934.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22114934.s7.e2" e2="DDI-PubMed.22114934.s7.e3" /></sentence><sentence text="" /></document>